Most clinical articles reported that DPP-4 inhibitors and GLP-1 analogs are neutral for adverse effects on HF; however, several remarkable studies have already been reported, and results of recent large-scale clinical trials are attracting public attention. Here, GLP1R is linked to hydrops fetalis.